1. Home
  2. HYFM vs ICU Comparison

HYFM vs ICU Comparison

Compare HYFM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hydrofarm Holdings Group Inc.

HYFM

Hydrofarm Holdings Group Inc.

HOLD

Current Price

$0.85

Market Cap

11.2M

Sector

Industrials

ML Signal

HOLD

Logo SeaStar Medical Holding Corporation

ICU

SeaStar Medical Holding Corporation

HOLD

Current Price

$4.23

Market Cap

9.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYFM
ICU
Founded
1977
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
9.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HYFM
ICU
Price
$0.85
$4.23
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.5K
246.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$134,252,000.00
N/A
Revenue This Year
$57.44
$93.92
Revenue Next Year
$5.71
$39.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.79
$0.22
52 Week High
$4.78
$4.93

Technical Indicators

Market Signals
Indicator
HYFM
ICU
Relative Strength Index (RSI) 41.67 66.02
Support Level $0.86 $2.26
Resistance Level $1.33 $4.93
Average True Range (ATR) 0.10 0.53
MACD -0.00 0.08
Stochastic Oscillator 27.44 76.08

Price Performance

Historical Comparison
HYFM
ICU

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.

Share on Social Networks: